PRIVA-MOXIFLOXACIN TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
09-12-2015
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)
Fáanlegur frá:
PHARMAPAR INC
ATC númer:
J01MA14
INN (Alþjóðlegt nafn):
MOXIFLOXACIN
Skammtar:
400MG
Lyfjaform:
TABLET
Samsetning:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
QUINOLONES
Vörulýsing:
Active ingredient group (AIG) number: 0142242001; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2019-08-29
Vara einkenni
_Priva-MOXIFLOXACIN _
_ _
_Page 1 of 60 _
PRODUCT MONOGRAPH
PR PRIVA-MOXIFLOXACIN
Moxifloxacin Tablets
(as moxifloxacin hydrochloride)
400 mg
Antibacterial Agent
PHARMAPAR INC.
DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse
October 16, 2015
Mont-Royal
Qc, H4T 1E2
CONTROL #: 187798
_Priva-MOXIFLOXACIN _
_ _
_Page 2 of 60 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
5
WARNINGS AND PRECAUTIONS
............................................................................................................
5
ADVERSE REACTIONS
...........................................................................................................................
12
DRUG INTERACTIONS
............................................................................................................................
15
DOSAGE AND ADMINISTRATION
........................................................................................................
17
OVERDOSAGE
..........................................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
19
STORAGE AND STABILITY
....................................................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
............
Lestu allt skjalið
